Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The SOUND Trial: Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Related Hearing Loss
2023-503313-30-01Phase 3Suspended
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sodium thiosulfate in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Clinically relevant benefit of transtympanic STS against cisplatin-induced hearing loss. Started Oct 2023; status: suspended.
02
Drugs
sodium thiosulfate
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-503313-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503313-30-01.